About this trial
AICA-Ribosiduria due to ATIC deficiency is a rare genetic metabolic disease that affects less than 10 patients (PMID: 32557644). It results in severe polyhandicap linked to neurodevelopmental disorders, visual impairment, growth retardation, severe spinal deformities and scoliosis, and often early-onset epilepsy. The disease is caused by dysfunction of the ATIC enzyme, which is involved in de novo purine biosynthesis. A recent study (PMID: 38244287) reported a decrease in disease biomarkers in a single patient after 3 months on a purine-rich diet, which persisted for at least 1 year. The investigators propose to replicate this study on several patients to investigate the potential of this treatment for this severe orphan disease.
Eligibility criteria
Qualifiers
Individual affected by AICA-ribosiduria due to ATIC deficiency
Disqualifiers
None
Trial design
Treatments tested in this trial
- purine-rich diet
Treatment groups
Sponsors and collaborators
Centre Hospitalier Universitaire de Saint Etienne
Lead sponsor
University Hospital of Saint-Etienne
Collaborator